ZEVALIN

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Italy, Japan, Lithuania, Poland, South Africa, Spain, UK.

Active ingredients

The drug ZEVALIN contains one active pharmaceutical ingredient (API):

1

Ibritumomab tiuxetan (⁹⁰Y) UNII 4Q52C550XK - IBRITUMOMAB TIUXETAN

Ibritumomab tiuxetan (⁹⁰Y) is a recombinant murine IgG1 kappa monoclonal antibody specific for the B-cell antigen CD20. Ibritumomab tiuxetan targets the antigen CD20 which is located on the surface of malignant and normal B-lymphocytes. During B-cell maturation, CD20 is first expressed in the midstage of B-lymphoblast (pre-B-cell), and is lost during the final stage of B-cell maturation to plasma cells. It is not shed from the cell surface and does not internalise on antibody binding.

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZEVALIN Kit for radiopharmaceutical preparations for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XC	† Monoclonal antibodies	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents
Discover more medicines within L01XC
V10XX02	Ibritumomab tiuxetan [90Y]	V Various → V10 Therapeutic radiopharmaceuticals → V10X Other therapeutic radiopharmaceuticals → V10XX Various therapeutic radiopharmaceuticals
Discover more medicines within V10XX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1208203, 1811236
ES	Centro de información online de medicamentos de la AEMPS	03264001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	015623
FR	Base de données publique des médicaments	66364008
GB	Medicines & Healthcare Products Regulatory Agency	397977
HK	Department of Health Drug Office	54925
IT	Agenzia del Farmaco	036311013
JP	医薬品医療機器総合機構	4291414G1020, 4300450G1027
LT	Valstybinė vaistų kontrolės tarnyba	1031487
PL	Rejestru Produktów Leczniczych	100126554
ZA	Health Products Regulatory Authority	A39/35/0016